A review of data regarding PD-L1 expression as a predictive biomarker of response to checkpoint inhibition in lung cancer.
Houman Nourkeyhani, MD
Articles by Houman Nourkeyhani, MD
It is estimated that 1 in 63 individuals in the United States will develop renal cell carcinoma (RCC), making it among the most common cancers in the country.
Latest Updated Articles
Immune Checkpoint Inhibitors for Renal Cell CarcinomaPublished: November 25th 2014 | Updated:
PD-L1 as a Biomarker Predictive of Response to Checkpoint Inhibition in Lung CancerPublished: January 19th 2017 | Updated: